Last week’s hot topic on Lymphoma was about the FDA Approves Gazyva as Combo Treatment for Follicular Lymphomas Unresponsive to Rituxan written by Carolina Henriques.
The article is centered around Genentech‘s announcement that the U.S. Food and Drug Administration (FDA) has approved the combination of Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva for the treatment of people with follicular lymphoma who were unresponsive to, or whose lymphoma returned after a regimen containing Rituxan (rituximab).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?